



PATENT

Our Docket: P-NI 4552 **RECEIVED**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE JAN 07 2003

In re application of:)
J. Michael Salbaum)
Serial No.: 09/754,997)
Filed: January 4, 2001)
For: NOPE POLYPEPTIDES,)
ENCODING NUCLEIC ACIDS)
AND METHODS OF USE)

Examiner: L. Helms

TECH CENTER 1600/2900

Group Art Unit: 1642

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EV 237991009 US

DATE OF DEPOSIT: December 30, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS
ADDRESSED TO: COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231.

Susan Faye L. Francisco
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)
Susan Faye L. Francisco
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the Restriction Requirement mailed August 28, 2002, consideration of the following remarks is respectfully requested.

The Restriction Requirement alleges that the application is directed to five distinct and independent inventions. Provided below are the five inventions set forth in the Restriction Requirement.

Group I : Claims 1 through 4, directed to Nope polypeptides;

Group II : Claims 5 through 7, directed to an antibody specific for Nope;

Group III : Claim 8, directed to a method of detection with a Nope antibody;

Inventors: J. Michael Salbaum
Serial No.: 09/754,997
Filed: January 4, 2001
Page 2

Group IV : Claims 9 through 15 and 20, directed to nucleic acids encoding Nope, vectors and host cells, and kits; and

Group V : Claims 16 through 19, directed to a method of detecting Nope nucleic acids by hybridization.

Election of one of the inventions is required under 35 U.S.C. § 121. Although the restriction requirement is traversed for the reasons set forth below, Applicants elect the claims set forth in Group IV, claims 9 to 15 and 20, for examination.

The Restriction Requirement is traversed with respect to the division of the claims of Group IV from the claims of Groups V. While the claims of Groups IV and V are patentably distinct, it is submitted that a thorough search of the claims of either group will likely reveal art relevant to the examination of the claims of the other group. For example, a thorough search of the method claims of Group V, which are directed to methods of using the claimed oligonucleotides of Group IV, necessarily entails a search of the claims of Group IV. Thus, a thorough search of the claims of Group IV will, of necessity, reveal information relevant to the examination of the claims of Group V and, therefore, division of the claims into these groups would result in duplicative searches. Therefore, examination of the claims of Group IV with the claims of Group V together should not

Inventors: J. Michael Salbaum
Serial No.: 09/754,997
Filed: January 4, 2001
Page 3

be an undue burden on the Examiner. Accordingly, reconsideration of the restriction requirement is respectfully requested.

The Restriction Requirement also indicates that, if Group IV is elected, an election of species is required between species L-X, which are directed to specific SEQ ID NOS. Applicant elects for examination species L, DNA encoding SEQ ID NO:2.

Applicant elects the claims set forth in Group IV, claims 9-15 and 20, for examination. Applicant also elects species L, DNA encoding SEQ ID NO:2. Applicant respectfully requests that the Restriction Requirement be reconsidered and that the claims of Group IV be examined with the claims of Group V. The Examiner is invited to call the undersigned agent or Cathryn Campbell if there are any questions.

Respectfully submitted,


Deborah L. Cadena
Deborah L. Cadena
Registration No. 44,048
Telephone No.: (858) 535-9001
Facsimile No.: (858) 535-8949

December 30, 2002
Date
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122
USPTO CUSTOMER NO. 23601



UI-UK-U- #USP 1042

AMENDMENT TRANSMITTAL LETTER				DOCKET NUMBER: P-NI 4552
SERIAL NO: 09/754,997	FILING DATE: January 4, 2001	EXAMINER: L. Helms	GROUP ART UNIT:1642	RECEIVED JAN 07 2003 TECH CENTER 1600/29
INVENTION: NOPE POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE				

TO COMMISSIONER FOR PATENTS

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EV 237991009 US

DATE OF DEPOSIT: December 30, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS ADDRESSED TO: COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231.

Susan Fauci L. Franciscan
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)
Susan Fauci L. Franciscan
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Transmitted herewith is a Response to Restriction Requirement, mailed August 28, 2002, in the above-identified application.

- Small Entity status of this application has been established under 37 CFR 1.27.
- Petition for a three-month Extension of Time is enclosed (in duplicate).
- Terminal Disclaimer with fee under 37 C.F.R. 1.20(d) is enclosed.
- No additional claims fee is required.
- An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	20	-	20	-	0	x \$9	\$18
INDEPENDENT CLAIMS	5	-	5	-	0	x \$42	\$84
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		YES	X NO		\$140	\$280	= \$ 0
					TOTAL ADDITIONAL FEE		\$ 0

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

— Please charge my Deposit Account No. 03-0370 the amount of \$ _____. A duplicate copy of this sheet is enclosed.

Inventors: J. Michael Salbaum
Serial No.: 09/754,997
Filed: January 4, 2001
Page 2

- X A check in the amount of \$920.00 is enclosed, which covers the fee for a three-month extension of time.
- X The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Deborah L. Cadena
Registration No. 44,048
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601